Pediatric efficacy supplement for Videx EC.
D000293:Adolescent; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D001835:Body Weight; D002648:Child; D002675:Child, Preschool; D003692:Delayed-Action Preparations; D016049:Didanosine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D004304:Dosage Forms; D017277:Drug Approval; D004348:Drug Labeling; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D019380:Anti-HIV Agents; D003692:Delayed-Action Preparations; D004304:Dosage Forms; D018894:Reverse Transcriptase Inhibitors; D016049:Didanosine